In December 2016, Celgene’s and Juno Therapeutics’ (JUNO) novel investigational drug, JCAR017, was given breakthrough designation by the US Food and Drug Administration (or FDA).
On June 8, 2016, 77% of XBI’s stocks were trading above their 20-day moving averages, 69% were trading above their 50-day moving averages, and 69% were trading above their 100-day moving averages.
Three analysts recommended a “buy” for Agios (AGIO), eight analysts recommended a “hold,” and no analysts recommended a “sell” for the stock. Agios has a weight of 2.2% in XBI’s portfolio.
The iShares Nasdaq Biotechnology ETF (IBB) has 189 stocks in its portfolio. As of June 6, 2016, 87% of IBB’s stocks were trading above their 20-day moving averages.
Among the 18 mid-cap stocks that XBI holds in its portfolio, 17 declined and only one advanced on March 23. Mid-caps represent ~30% of XBI’s portfolio.
Kite Pharma and Juno Therapeutics led the Biotechnology group of the SPDR S&P Biotechnology ETF (XBI) for the week ending September 11. Kite Pharma and Juno Therapeutics rose 21.94% and 19.78%, respectively.
